377 related articles for article (PubMed ID: 33579328)
1. Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation.
Sonawane SK; Uversky VN; Chinnathambi S
Cell Commun Signal; 2021 Feb; 19(1):16. PubMed ID: 33579328
[TBL] [Abstract][Full Text] [Related]
2. Baicalein suppresses Repeat Tau fibrillization by sequestering oligomers.
Sonawane SK; Balmik AA; Boral D; Ramasamy S; Chinnathambi S
Arch Biochem Biophys; 2019 Oct; 675():108119. PubMed ID: 31568753
[TBL] [Abstract][Full Text] [Related]
3. Baicalein inhibits formation of α-synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation.
Lu JH; Ardah MT; Durairajan SS; Liu LF; Xie LX; Fong WF; Hasan MY; Huang JD; El-Agnaf OM; Li M
Chembiochem; 2011 Mar; 12(4):615-24. PubMed ID: 21271629
[TBL] [Abstract][Full Text] [Related]
4. Curcumin Inhibits Tau Aggregation and Disintegrates Preformed Tau Filaments in vitro.
Rane JS; Bhaumik P; Panda D
J Alzheimers Dis; 2017; 60(3):999-1014. PubMed ID: 28984591
[TBL] [Abstract][Full Text] [Related]
5. Hsp40s play complementary roles in the prevention of tau amyloid formation.
Irwin R; Faust O; Petrovic I; Wolf SG; Hofmann H; Rosenzweig R
Elife; 2021 Aug; 10():. PubMed ID: 34369377
[TBL] [Abstract][Full Text] [Related]
6. The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios.
Wobst HJ; Sharma A; Diamond MI; Wanker EE; Bieschke J
FEBS Lett; 2015 Jan; 589(1):77-83. PubMed ID: 25436420
[TBL] [Abstract][Full Text] [Related]
7. Amyloidogenesis of Tau protein.
Nizynski B; Dzwolak W; Nieznanski K
Protein Sci; 2017 Nov; 26(11):2126-2150. PubMed ID: 28833749
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the Self-Assembly of Aβ and of Tau by Polyphenols: Mechanistic Studies.
Zheng Q; Kebede MT; Kemeh MM; Islam S; Lee B; Bleck SD; Wurfl LA; Lazo ND
Molecules; 2019 Jun; 24(12):. PubMed ID: 31234523
[TBL] [Abstract][Full Text] [Related]
9. Integrating in vitro and in silico approaches to evaluate the "dual functionality" of palmatine chloride in inhibiting and disassembling Tau-derived VQIVYK peptide fibrils.
Haj E; Losev Y; Guru KrishnaKumar V; Pichinuk E; Engel H; Raveh A; Gazit E; Segal D
Biochim Biophys Acta Gen Subj; 2018 Jul; 1862(7):1565-1575. PubMed ID: 29634991
[TBL] [Abstract][Full Text] [Related]
10. Oligomer Diversity during the Aggregation of the Repeat Region of Tau.
Kjaergaard M; Dear AJ; Kundel F; Qamar S; Meisl G; Knowles TPJ; Klenerman D
ACS Chem Neurosci; 2018 Dec; 9(12):3060-3071. PubMed ID: 29953200
[TBL] [Abstract][Full Text] [Related]
11. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
12. Methylene Blue Inhibits Formation of Tau Fibrils but not of Granular Tau Oligomers: A Plausible Key to Understanding Failure of a Clinical Trial for Alzheimer's Disease.
Soeda Y; Saito M; Maeda S; Ishida K; Nakamura A; Kojima S; Takashima A
J Alzheimers Dis; 2019; 68(4):1677-1686. PubMed ID: 30909223
[TBL] [Abstract][Full Text] [Related]
13. Nonphosphorylated tau slows down Aβ
Beeg M; Battocchio E; De Luigi A; Colombo L; Natale C; Cagnotto A; Corbelli A; Fiordaliso F; Diomede L; Salmona M; Gobbi M
J Biol Chem; 2021; 296():100664. PubMed ID: 33865852
[TBL] [Abstract][Full Text] [Related]
14. Polyphenol-Peptide Interactions in Mitigation of Alzheimer's Disease: Role of Biosurface-Induced Aggregation.
Gaudreault R; Hervé V; van de Ven TGM; Mousseau N; Ramassamy C
J Alzheimers Dis; 2021; 81(1):33-55. PubMed ID: 33749653
[TBL] [Abstract][Full Text] [Related]
15. Resonance Raman spectroscopic measurements delineate the structural changes that occur during tau fibril formation.
Ramachandran G; Milán-Garcés EA; Udgaonkar JB; Puranik M
Biochemistry; 2014 Oct; 53(41):6550-65. PubMed ID: 25284680
[TBL] [Abstract][Full Text] [Related]
16. Exploring the inhibitory effects of liquiritigenin against tau fibrillation and related neurotoxicity as a model of preventive care in Alzheimer's disease.
Yuan X; Wang Z; Zhang L; Sui R; Khan S
Int J Biol Macromol; 2021 Jul; 183():1184-1190. PubMed ID: 33965487
[TBL] [Abstract][Full Text] [Related]
17. Can any "non-specific charge modification within microtubule binding domains of Tau" be a prerequisite of the protein amyloid aggregation? An in vitro study on the 1N4R isoform.
Jangholi A; Ashrafi-Kooshk MR; Arab SS; Karima S; Poorebrahim M; Ghadami SA; Moosavi-Movahedi AA; Khodarahmi R
Int J Biol Macromol; 2018 Apr; 109():188-204. PubMed ID: 29248553
[TBL] [Abstract][Full Text] [Related]
18. Azure C Targets and Modulates Toxic Tau Oligomers.
Lo Cascio F; Kayed R
ACS Chem Neurosci; 2018 Jun; 9(6):1317-1326. PubMed ID: 29378132
[TBL] [Abstract][Full Text] [Related]
19. HspB1 and Hsc70 chaperones engage distinct tau species and have different inhibitory effects on amyloid formation.
Baughman HER; Clouser AF; Klevit RE; Nath A
J Biol Chem; 2018 Feb; 293(8):2687-2700. PubMed ID: 29298892
[TBL] [Abstract][Full Text] [Related]
20. Modeling Prion-Like Processing of Tau Protein in Alzheimer's Disease for Pharmaceutical Development.
Wischik CM; Schelter BO; Wischik DJ; Storey JMD; Harrington CR
J Alzheimers Dis; 2018; 62(3):1287-1303. PubMed ID: 29226873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
